Doogan Declan's Form 4/A amendment
AmendedBiohaven Pharmaceutical Holding Co Ltd. · filed Feb 11, 2022
- Accession no.
- 0001562180-22-001434
- Filed
- Feb 11, 2022
- Trade date
- Jun 11-12, 2020
- Filing delay
- 610 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jun 12, 2020
This filing lists 4 non-derivative transactions. Open-market sales total $3.32M. It was filed 610 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Doogan DeclanCIK 0001704234 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2020 | Common Shares | SSaleDisposed | −11,706 | $64.42F1 | −$754,100.52 | 859,335 | Indirect | |
| Jun 11, 2020 | Common Shares | SSaleDisposed | −13,333 | $64.71F3 | −$862,778.43 | 360,580 | Direct | |
| Jun 12, 2020 | Common Shares | SSaleDisposed | −12,580 | $65.55F4 | −$824,619 | 792,669 | Indirect | |
| Jun 12, 2020 | Common Shares | SSaleDisposed | −13,334 | $66.01F5 | −$880,177.34 | 347,246 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.31 - $64.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 12, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.54 - $65.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 - $65.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.79 - $66.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.